



Claims

1. Compounds S2502 and S2507 having the formulae

5



S2502



S2507

10

or their pharmaceutically acceptable salts for use as a medicament or in drug development.

2. The compounds S2502 and S2507 as defined in claim 1, or their structural analogues or
15 their pharmaceutically acceptable salts for use in a method of prophylactic treatment of human or animal body.

3. Use of the compounds S2502 and S2507 as defined in claim 1, or their structural analogues or their pharmaceutically acceptable salts in the manufacture of a medicament
20 for the treatment of virus infections.

4. Use of the compounds S2502 and S2507 as defined in claim 1, or their structural analogues or their pharmaceutically acceptable salts in the manufacture of a medicament for the treatment of cancer.

25

5. A pharmaceutical composition comprising a compound selected from the group consisting of the compounds S2502 and S2507 as defined in claim 1, structural analogues

of these compounds and pharmaceutically acceptable salts of these compounds, in association with a pharmaceutically acceptable carrier.

5 6. A method for the treatment of cancer, comprising administering to a patient in need of such treatment an efficacious amount of the pharmaceutical composition according to claim 5.

10 7. A method for the treatment of virus infections, comprising administering to a patient in need of such treatment an efficacious amount of the pharmaceutical composition according to claim 5.